UB Paderborn / Katalog / Suche / in CDI

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

Journal of the National Comprehensive Cancer Network, 2022-11, Vol.20 (11), p.1204

2022

Volltextzugriff (PDF)

(P090) Stereotactic Radiosurgery for Brain Metastases From Primary Head and Neck Carcinomas: A Retrospective Analysis

International journal of radiation oncology, biology, physics, 2017-06, Vol.98 (2), p.E39-E40

2017

Volltextzugriff (PDF)

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A843-A843

2020

Volltextzugriff (PDF)

The role of inhibitors of the epidermal growth factor in management of head and neck cancer

Journal of the National Comprehensive Cancer Network, 2008-08, Vol.6 (7), p.696

2008

Volltextzugriff (PDF)

Phase 1/2 study of devimistat in combination with hydroxychloroquine (HCQ) in patients with relapsed or refractory (R/R) clear cell sarcoma (CCS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS11595-TPS11595

2022

Volltextzugriff (PDF)

Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer

The journal of clinical endocrinology and metabolism, 2024-08

2024

Volltextzugriff (PDF)

OER-073: A Multi-Center Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma

Cancer, 2022-08, Vol.128 (19), p.3516-3522

2022

Volltextzugriff (PDF)

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11565-11565

2023

Volltextzugriff (PDF)

A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11562-11562

2021

Volltextzugriff (PDF)

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1291-1300

2022

Volltextzugriff (PDF)

Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e18743-e18743

2018

Volltextzugriff (PDF)

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11531-11531

2023

Volltextzugriff (PDF)

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11505-11505

2023

Volltextzugriff (PDF)

Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis

Cancer, 2008-09, Vol.113 (6), p.1446-1452

2008

Volltextzugriff (PDF)

Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.11039-11039

2019

Volltextzugriff (PDF)

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11562-11562

2020

Volltextzugriff (PDF)

Management of salivary gland malignancies: current and developing therapies

Oncology reviews, 2011-12, Vol.2 (2), p.86

2011

Volltextzugriff (PDF)

SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS11569-TPS11569

2020

Volltextzugriff (PDF)

Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11561-11561

2020

Volltextzugriff (PDF)

A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11567-11567

2021

Volltextzugriff (PDF)

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11505-11505

2021

Volltextzugriff (PDF)

Abstract CT165: Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT165-CT165

2023

Volltextzugriff (PDF)

Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review

Oncotarget, 2018-06, Vol.9 (46), p.28281-28289

2018

Volltextzugriff (PDF)

Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11564-11564

2020

Volltextzugriff (PDF)

Evaluating the Supportive Care Costs of Severe Radiochemotherapy-lnduced Mucositis and Pharyngitis : Results From a Northwestern University Costs of Cancer Program Pilot Study With Head and Neck and Nonsmall Cell Lung Cancer Patients Who Received Care at a County Hospital, a Veterans Administration Hospital, or a Comprehensive Cancer Care Center

Cancer, 2008-09, Vol.113 (6), p.1446-1452

2008

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

(P090) Stereotactic Radiosurgery for Brain Metastases From Primary Head and Neck Carcinomas: A Retrospective Analysis

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

The role of inhibitors of the epidermal growth factor in management of head and neck cancer

Phase 1/2 study of devimistat in combination with hydroxychloroquine (HCQ) in patients with relapsed or refractory (R/R) clear cell sarcoma (CCS)

Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer

OER-073: A Multi-Center Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1

Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas

Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis

Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS)

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304)

Management of salivary gland malignancies: current and developing therapies

SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma

A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Abstract CT165: Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors

Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review

Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma

Aktive Filter

Suchergebnisse filtern